Neurocrine Biosciences (Nasdaq: NBIX) announced that its Phase 3 KINECT-DCP study of valbenazine in pediatric and adult participants with dyskinetic cerebral palsy did not meet primary or key secondary endpoints (Dec. 22, 2025).
The 14-week, double-blind, placebo-controlled study—described as the largest trial ever completed in DCP—assessed improvement in chorea. Adverse events were reported as generally consistent with valbenazine's established safety profile.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.